Ultrasensitive Protein Detection in Cancer.

Abstract

Circulating protein biomarkers may offer a minimally invasive way to diagnose and follow cancers, yet their clinical utility has been limited by biological and analytical constraints. Recent advances in ultrasensitive protein detection have enabled quantification of low-abundance analytes that were previously inaccessible but potentially informative. These capabilities have renewed interest in circulating proteins as cancer biomarkers. Interpreting ultrasensitive protein measurements within cancer pathology requires understanding how biological processes shape their detectability and clinical meaning. Improved analytical sensitivity also enables a shift from static diagnostic cutoffs to dynamic readouts that track tumor-host signaling and residual disease kinetics longitudinally. Distinct clinical contexts, from screening and early detection to monitoring disease burden and therapeutic response, impose unique requirements on assay performance and clinical interpretation. Major classes of ultrasensitive detection strategies are evaluated with respect to how effectively they address practice needs, together with translational challenges including clinical validation, assay standardization, and integration into existing clinical workflows. Meaningful patient impact will require a constellation of factors, from disease biology and analytical design to pathological interpretation and clinical actionability.